UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
114,46 USD
arrow_downward
-0,87%(-1,01) 1D
16-окт., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
114,95 USD
High
115,28 USD
Low
114,23 USD
Mkt. cap
39,39 млд
Avg. vol.
53,31 миң
Volume
70,57 миң
52-wk high
168,76 USD
52-wk low
110,55 USD
Beta
0,57
Shares outstanding
389,01 млн
No. of employees
9 миң
Open
114,95 USD
High
115,28 USD
Low
114,23 USD
Mkt. cap
39,39 млд
Avg. vol.
53,31 миң
Volume
70,57 миң
52-wk high
168,76 USD
52-wk low
110,55 USD
Beta
0,57
Shares outstanding
389,01 млн
No. of employees
9 миң
News stories
From web sources and news partners
ad-hoc-news.de
·
5 саат мурун
UCB wins FDA approval for ZILBRYSQ autoinjector and UCB stock costs EUR 203.00
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOJean-Christophe Tellier
Employees9 миң
Founded1928-ж., 18-янв.
Headquarters-
SectorPharmaceutical industry
Websiteucb.com